Updated data from the pivotal phase III STARGLO study continue to demonstrate a clinically meaningful improvement in overall ...

Swiss healthcare company Roche (RHHBY) on Friday said that the European Medicines Agency’s Committee for Medicinal Products ...

Swiss pharma major Roche (ROG: SIX) has reported updated results from its Phase III STARGLO trial, showing that a ...

The FDA’s Oncologic Drugs Advisory Committee voted against an application for Columvi (glofitamab) plus GemOx for ...

After a median follow-up of 24.7 months, data showed a 40% improvement in overall survival (OS) for patients treated with Columvi (glofitamab-gxbm) in combination with gemcitabine and oxaliplatin ...

The ODAC cited concerns with patient populations in clinical trials used to support the proposed expansion. Johnson & Johnson ...

Roche provides update on US FDA Advisory Committee meeting on Columvi combination for people with relapsed or refractory DLBCL: Basel Thursday, May 22, 2025, 12:00 Hrs [IST] Roche ...

The FDA'S ODAC has casted their votes on the use of certain treatments in both the relapsed/refractory DLBCL and myeloma ...

What's more, both FDA Commissioner Martin Makary, M.D., and longtime FDA oncology chief Richard Pazdur, M.D., have a new ...

Genentech, a Roche Group company (OTCQX:RHHBY) (OTCQX:RHHBF), said on Tuesday that a U.S. FDA advisory committee voted ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today two-year follow-up data from the Phase ...

New Two-year Follow-up of Genentech’s Columvi Extends Overall Survival in Relapsed or Refractory Diffuse Large B-cell Lymphoma Patients – Updated data from the pivotal Phase III STARGLO study ...